leukotriene-c4 and Melanoma

The expression of several drug-resistance genes, including MRP and p53, increases with advancing stage of human prostate cancer. Altered transcription could account for the genotypic alterations associated with prostate cancer progression, and it was recently reported that the promoter of MRP1 is activated in the presence of mutant p53. To determine whether there is a relationship between p53 status and the expression of MRP1, a human, temperature-sensitive p53 mutant (tsp Val(138)) was transfected into LNCaP human prostate cancer cells. In the transfected cell line (LVCaP), the wild-type p53 produced growth arrest at the G1/S interface of the cell cycle, inhibited colony formation, and induced p21(waf1/cip1). Temperature shifting to 38 degrees C (p53 mutant) produced a time-dependent increase in expression of MRP1. This change in MRP1 expression was also seen in isogenic cell lines in which p53 was inactivated by human papilloma virus (HPV)16E6 protein or by a dominant-negative mutant. Functional assays revealed a decrease in drug accumulation and drug sensitivity associated with mutant p53 and increased MRP1 expression. These results provide the first mechanistic link between expression of MRP1 and mutation of p53 in human prostate cancer and support recent clinical associations. Furthermore, these data suggest a mechanism tying accumulation of p53 mutations to the multidrug resistance phenotype seen in this disease.

Topics: Antineoplastic Agents; Carcinoma; Cell Cycle; Clone Cells; Colonic Neoplasms; DNA-Binding Proteins; Dose-Response Relationship, Drug; Doxorubicin; Flow Cytometry; Humans; Leukotriene C4; Male; Melanoma; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Prostatic Neoplasms; Recombinant Proteins; Transfection; Tumor Suppressor Protein p53; Vincristine

We examined the synthesis of leukotrienes (LTs) in human melanoma cells in order to assess the function of LTs in human melanocytes. LTA4 hydrolase, which catalyzes the conversion of LTA4 to LTB4, was detected in the supernatant of cultured human melanoma (MeWo) cells and melanoma cells obtained from patients. Immunoblotting analysis using an antihuman LTA4 hydrolase antibody showed LTA4 hydrolase to be a 70-kDa protein in both MeWo and melanoma cells. Considerable activity of LTC4 synthase, which catalyzes the conversion of LTA4 to LTC4, was detected in the microsomal fraction of both MeWo and melanoma cells. The HPLC profile of the LTC4 synthase reaction products revealed that LTC4 was the main product. LTD4 was not detected under these conditions, indicating that the microsomal fraction of human melanoma cells lacks the membrane-bound gamma-glutamyl transferase that converts LTC4 to LTD4. LTC4 synthase activity was inhibited by the addition of MK-886, and was not altered by treatment with N-ethylmaleimide or 1-chloro-2,4-dinitrobenzene. These results indicate that the enzyme responsible for the conversion of LTA4 to LTC4 in human melanoma cells is LTC4 synthase rather than a nonspecific or microsomal glutathione-S-transferase. These results also suggest that human melanoma cells can generate LTB4 and LTC4 from LTA4, and that this process is catalyzed by two enzymes: LTA4 hydrolase and LTC4 synthase.

Topics: Dinitrochlorobenzene; Enzyme Inhibitors; Epoxide Hydrolases; Ethylmaleimide; Glutathione Transferase; Humans; Indoles; Leukotriene A4; Leukotriene B4; Leukotriene C4; Leukotriene D4; Melanoma; Microsomes; Tumor Cells, Cultured